2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Neurodegenerative Diseases D019636 32 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Neuralgia D009437 28 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Acute Pain D059787 3 associated lipids
Fetal Nutrition Disorders D048070 1 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
DeVuono MV et al. Conditioned gaping produced by high dose Δ-tetrahydracannabinol: Dysregulation of the hypothalamic endocannabinoid system. 2018 Neuropharmacology pmid:30195587
Atwood BK et al. CBâ‚‚ cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. 2012 Neuropharmacology pmid:22579668
Shimizu T et al. Possible inhibitory role of endogenous 2-arachidonoylglycerol as an endocannabinoid in (±)-epibatidine-induced activation of central adrenomedullary outflow in the rat. 2015 Neuropharmacology pmid:25882827
Eroli F et al. Differential neuromodulatory role of endocannabinoids in the rodent trigeminal sensory ganglion and cerebral cortex relevant to pain processing. 2018 Neuropharmacology pmid:29225040
Walentiny DM et al. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice. 2015 Neuropharmacology pmid:25698527
Kortleven C et al. Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. 2012 Neuropharmacology pmid:22884466
Nader J et al. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. 2014 Neuropharmacology pmid:24709540
Pasquarelli N et al. Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue. 2015 Neuropharmacology pmid:25497453
Moreira FA et al. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. 2008 Neuropharmacology pmid:17709120
Morena M et al. Emotional arousal state influences the ability of amygdalar endocannabinoid signaling to modulate anxiety. 2016 Neuropharmacology pmid:27553121
Vellani V et al. Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. 2008 Neuropharmacology pmid:18329052
Darmani NA et al. Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. 2005 Neuropharmacology pmid:15921709
Desroches J et al. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. 2014 Neuropharmacology pmid:24148808
Morgan NH et al. Functional CB2 type cannabinoid receptors at CNS synapses. 2009 Neuropharmacology pmid:19616018
Wilkerson JL et al. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. 2017 Neuropharmacology pmid:27890602
Piomelli D The endogenous cannabinoid system and the treatment of marijuana dependence. 2004 Neuropharmacology pmid:15464150
Placzek EA et al. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. 2008 Neuropharmacology pmid:18760289
Covey DP et al. Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease. 2018 Neuropsychopharmacology pmid:29925886
Wills KL et al. Double Dissociation of Monoacylglycerol Lipase Inhibition and CB1 Antagonism in the Central Amygdala, Basolateral Amygdala, and the Interoceptive Insular Cortex on the Affective Properties of Acute Naloxone-Precipitated Morphine Withdrawal in Rats. 2016 Neuropsychopharmacology pmid:26647976
Viganò D et al. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. 2003 Neuropsychopharmacology pmid:12637958
Morena M et al. Enhancing Endocannabinoid Neurotransmission Augments The Efficacy of Extinction Training and Ameliorates Traumatic Stress-Induced Behavioral Alterations in Rats. 2018 Neuropsychopharmacology pmid:29265107
Morena M et al. Neurobiological Interactions Between Stress and the Endocannabinoid System. 2016 Neuropsychopharmacology pmid:26068727
Sumislawski JJ et al. Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. 2011 Neuropsychopharmacology pmid:21849983
Dubreucq S et al. Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. 2012 Neuropsychopharmacology pmid:22434220
Oleson EB et al. Cannabinoid receptor activation shifts temporally engendered patterns of dopamine release. 2014 Neuropsychopharmacology pmid:24345819
Sarchielli P et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. 2007 Neuropsychopharmacology pmid:17119542
Blasio A et al. Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala. 2013 Neuropsychopharmacology pmid:23793355
Patel S et al. Repeated homotypic stress elevates 2-arachidonoylglycerol levels and enhances short-term endocannabinoid signaling at inhibitory synapses in basolateral amygdala. 2009 Neuropsychopharmacology pmid:19675536
Maccarrone M et al. Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. 2010 Neuropsychopharmacology pmid:20393458
Lim J et al. Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats. 2016 Neuropsychopharmacology pmid:26361059
Cristino L et al. Orexin-A and Endocannabinoid Activation of the Descending Antinociceptive Pathway Underlies Altered Pain Perception in Leptin Signaling Deficiency. 2016 Neuropsychopharmacology pmid:26081302
Pérez-Morales M et al. 2-Arachidonoylglycerol into the lateral hypothalamus improves reduced sleep in adult rats subjected to maternal separation. 2014 Neuroreport pmid:25356522
Beltramo M and Piomelli D Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. 2000 Neuroreport pmid:10817598
Rubio M et al. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. 2007 Neurosci. Lett. pmid:17574742
Sinor AD et al. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. 2000 Neurosci. Lett. pmid:10653017
Sugiura T et al. Rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain after decapitation. 2001 Neurosci. Lett. pmid:11137756
Maison P et al. BDNF regulates neuronal sensitivity to endocannabinoids. 2009 Neurosci. Lett. pmid:19818836
Urbanski MJ et al. Endocannabinoid-mediated synaptically evoked suppression of GABAergic transmission in the cerebellar cortex. 2010 Neuroscience pmid:20553815
Zhang L et al. Endocannabinoid 2-AG and intracellular cannabinoid receptors modulate a low-threshold calcium spike-induced slow depolarizing afterpotential in rat thalamic paraventricular nucleus neurons. 2016 Neuroscience pmid:26924019
Turunen PM et al. Endocannabinoid Signaling in Embryonic Neuronal Motility and Cell-Cell Contact - Role of mGluR5 and TRPC3 Channels. 2018 Neuroscience pmid:29438802
Dowie MJ et al. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. 2009 Neuroscience pmid:19524019
Straiker A and Mackie K Cannabinoid signaling in inhibitory autaptic hippocampal neurons. 2009 Neuroscience pmid:19501632
Pascual AC et al. 2-Arachidonoylglycerol metabolism is differently modulated by oligomeric and fibrillar conformations of amyloid beta in synaptic terminals. 2017 Neuroscience pmid:28844762
Roberts CJ et al. Swim stress differentially affects limbic contents of 2-arachidonoylglycerol and 2-oleoylglycerol. 2012 Neuroscience pmid:22192839
Musella A et al. Transient receptor potential vanilloid 1 channels control acetylcholine/2-arachidonoylglicerol coupling in the striatum. 2010 Neuroscience pmid:20219639
Ludányi A et al. Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. 2011 Neuroscience pmid:21035522
Veeraraghavan P et al. A study of cannabinoid-1 receptors during the early phase of excitotoxic damage to rat spinal locomotor networks in vitro. 2016 Neuroscience pmid:27450568
Palkovits M et al. Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. 2008 Neuroscience pmid:18343585
Yang W et al. Cannabinoid receptor agonists modulate calcium channels in rat retinal Müller cells. 2016 Neuroscience pmid:26621126
Chen X et al. Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults. 2011 Neuroscience pmid:21256197
Petrosino S et al. Alteration of the endocannabinoid system in mouse brain during prion disease. 2011 Neuroscience pmid:21195746
Ikeda H et al. Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice. 2013 Neuroscience pmid:23892011
Sticht MA et al. Intra-visceral insular cortex 2-arachidonoylglycerol, but not N-arachidonoylethanolamide, suppresses acute nausea-induced conditioned gaping in rats. 2015 Neuroscience pmid:25499318
Palmer JA et al. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse. 2008 Neuroscience pmid:18541380
Hutch CR et al. An endocannabinoid system is present in the mouse olfactory epithelium but does not modulate olfaction. 2015 Neuroscience pmid:26037800
Gopez JJ et al. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. 2005 Neurosurgery pmid:15730585
Smaga I et al. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. 2014 Neurotox Res pmid:24652522
Smaga I et al. Changes in the Brain Endocannabinoid System in Rat Models of Depression. 2017 Neurotox Res pmid:28247204
Carr RL et al. Decreased anxiety in juvenile rats following exposure to low levels of chlorpyrifos during development. 2017 Neurotoxicology pmid:26642910
Rademacher DJ et al. Waterborne lead exposure affects brain endocannabinoid content in male but not female fathead minnows (Pimephales promelas). 2005 Neurotoxicology pmid:15527869
Liu J et al. Comparative effects of parathion and chlorpyrifos on endocannabinoid and endocannabinoid-like lipid metabolites in rat striatum. 2015 Neurotoxicology pmid:26215119
Tsuyama S et al. Dietary conjugated linoleic acid modifies the brain endocannabinoid system in mice. 2009 Nutr Neurosci pmid:19622239
Haas MJ et al. Inhibition of apolipoprotein A-I gene expression by obesity-associated endocannabinoids. 2012 Obesity (Silver Spring) pmid:22016100
Gonthier MP et al. Identification of endocannabinoids and related compounds in human fat cells. 2007 Obesity (Silver Spring) pmid:17426318
Starowicz KM et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. 2008 Obesity (Silver Spring) pmid:18239598
Zelber-Sagi S et al. Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease. 2017 Obesity (Silver Spring) pmid:27863097
Abdulnour J et al. Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. 2014 Obesity (Silver Spring) pmid:23616305
Engeli S et al. Peripheral endocannabinoid system activity in patients treated with sibutramine. 2008 Obesity (Silver Spring) pmid:18356837
Motaghedi R and McGraw TE The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. 2008 Obesity (Silver Spring) pmid:18551116
Bernabò N et al. Systems biology analysis of the endocannabinoid system reveals a scale-free network with distinct roles for anandamide and 2-arachidonoylglycerol. 2013 OMICS pmid:24117401
Echigo R et al. Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells. 2012 Oncol. Rep. pmid:22842590
Orellana-Serradell O et al. Proapoptotic effect of endocannabinoids in prostate cancer cells. 2015 Oncol. Rep. pmid:25606819
Vujic N et al. Monoglyceride lipase deficiency affects hepatic cholesterol metabolism and lipid-dependent gut transit in ApoE-/- mice. 2017 Oncotarget pmid:28380440
Rea K et al. Evidence for a role of GABAergic and glutamatergic signalling in the basolateral amygdala in endocannabinoid-mediated fear-conditioned analgesia in rats. 2013 Pain pmid:23414578
Telleria-Diaz A et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. 2010 Pain pmid:19879047
Bradshaw H CB1-induced side effects of specific COX-2 inhibitors: a feature, not a bug. 2010 Pain pmid:19913999
La Porta C et al. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. 2015 Pain pmid:26067584
Carloni S et al. Pretreatment with the monoacylglycerol lipase inhibitor URB602 protects from the long-term consequences of neonatal hypoxic-ischemic brain injury in rats. 2012 Pediatr. Res. pmid:22821058
den Boon FS et al. Endocannabinoids produced upon action potential firing evoke a Cl(-) current via type-2 cannabinoid receptors in the medial prefrontal cortex. 2014 Pflugers Arch. pmid:24671573
Carrasquer A et al. Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor. 2010 Pharmacogenet. Genomics pmid:20124950
Pérez-Morales M et al. 2-AG into the lateral hypothalamus increases REM sleep and cFos expression in melanin concentrating hormone neurons in rats. 2013 Pharmacol. Biochem. Behav. pmid:23603032
Wakley AA and Rasmussen EB Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats. 2009 Pharmacol. Biochem. Behav. pmid:19602424
Stanley CP and O'Sullivan SE Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. 2014 Pharmacol. Res. pmid:24548820
Eisenstein SA et al. A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. 2010 Pharmacol. Res. pmid:20044005
Deshmukh RR and Sharma PL Stimulation of accumbens shell cannabinoid CB(1) receptors by noladin ether, a putative endocannabinoid, modulates food intake and dietary selection in rats. 2012 Pharmacol. Res. pmid:22728691
Khasabova IA et al. JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy. 2014 Pharmacol. Res. pmid:25304184
Navarria A et al. The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. 2014 Pharmacol. Res. pmid:24861565
Spradley JM et al. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. 2010 Pharmacol. Res. pmid:20416378
Leishman E et al. Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain. 2016 Pharmacol. Res. pmid:27109320
Guindon J et al. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. 2013 Pharmacol. Res. pmid:23127915
Sciolino NR et al. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. 2011 Pharmacol. Res. pmid:21600985
Stefano GB et al. 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. 2000 Pharmacol. Res. pmid:10987990
Malek N et al. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. 2016 Pharmacol. Res. pmid:27326920
Fowler CJ and Ghafouri N Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? 2008 Pharmacol. Res. pmid:18675915
Nicolussi S et al. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. 2014 Pharmacol. Res. pmid:24412246
Khasabova IA et al. Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. 2011 Pharmacol. Res. pmid:21440630
Bakas T et al. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA receptors. 2017 Pharmacol. Res. pmid:28249817
Pagano E et al. Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis. 2017 Pharmacol. Res. pmid:28193521
Straiker A et al. Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model. 2015 Pharmacol. Res. pmid:26211948
Imperatore R et al. Formation of OX-1R/CB1R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation. 2016 Pharmacol. Res. pmid:27436148